Acrivon Therapeutics, Inc. filed a Current Report on Form 8-K dated November 10, 2026, disclosing details from a corporate Research and Development (R&D) event hosted by the company. The event was a webcast featuring Key Opinion Leaders (KOLs) to discuss Acrivon’s new immunology and inflammation (I&I) programs, which were identified using the company’s proprietary AI-driven AP3 platform.
The presentation introduced two preclinical programs for the treatment of Eosinophilic esophagitis (EoE): ACR-525 and a PKCθ inhibitor. ACR-525 is described as a Phase 2-ready, oral, selective JAK1 inhibitor, also known by the code name AQ280. The company highlighted that ACR-525 has undergone extensive AP3 profiling against approved JAK inhibitors and dupilumab, noting that it is highly JAK1-selective and oral.
According to the filing, ACR-525 demonstrates a differentiated profile with desirable global phospho-proteomic pathway effects. The company noted that the compound suppresses TGFb signaling, a potential anti-fibrotic mechanism, and does not activate pro-apoptotic BAD signaling, which is cited as a potential safety advantage. Clinical data from Phase 1 studies in healthy volunteers reportedly support once-daily oral dosing, showing dose-proportional pharmacokinetics and favorable initial safety and tolerability.
The filing also detailed the epidemiology of EoE, citing data indicating a significant increase in the patient population over the past 25 years. The report states that the prevalence of EoE in the United States rose from 28.3 per 100,000 people in 2009 to 163.1 per 100,000 people in 2022, representing a total increase of 477% over 13 years. The presentation outlined the current standard of care and unmet needs for patients, including the inability to pass solid foods and the need for long-term treatment to prevent esophageal scarring.
